Beneficial Ownership Report · SCHEDULE 13D/A
CVRx, Inc.
CVRXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13D/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- CVRx, Inc.
- Company CIK
- 0001235912
- Street
- 9201 WEST BROADWAY AVENUE
- Street (continued)
- SUITE 650
- City
- MINNEAPOLIS
- State / country code
- MN
- Postal code
- 55445
Statement details
- Amendment number
- 1
- Security class
- Common Stock, $0.01 par value
- Event date
- 09/30/2026
- Previously filed indication
- true
Authorized notification person 1
- Name
- Jorey Chernett
- Phone
- 248-469-8811
- Street
- 6222 Indianwood Tr.
- Street (continued)
- SUITE 650
- City
- Bloomfield Hills
- State / country code
- MI
- Postal code
- 48301
Reporting person 1
- Name
- Chernett Jorey
- Reporting person CIK
- 0002042077
- No reporting person CIK indication
- N
- Citizenship / organization
- X1
- Reporting person type
- IN
- Source of funds code
- PF
- Legal proceedings indication
- N
- Aggregate amount owned
- 165,000.00
- Percent of class
- 0.62
- Sole voting power
- 165,000.00
- Shared voting power
- 0.00
- Sole dispositive power
- 165,000.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- This Amendment No. 1 constitutes an exit filing for the Reporting Person, as the Reporting Person no longer beneficially owns more than five percent of the outstanding shares of the Issuer.
Item 1
Issuer
CVRx, Inc.
Security title
Common Stock, $0.01 par value
Principal address
Comment
The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1"). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Schedule 13D. As a result of the transactions described herein, the filing of this Amendment No. 1 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.
Item 3
Source of funds
Item 3 is hereby amended and restated to read as follows: The 165,000 Shares held by Mr. Chernett were acquired through private transactions using personal funds in the amount of $475,200.
Item 4
Purpose of transaction
Item 4 is hereby amended to add the following: This Amendment No. 1 is being filed to report that, following a difference of opinion with the Issuer's management regarding the Issuer's strategic direction, the Reporting Person has sold Shares and, as a result, no longer beneficially owns more than five percent of the outstanding Shares.
Item 5
Number of shares
Item 5(b) is hereby amended and restated to read as follows: 1. Sole power to vote or direct vote: 165,000 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 165,000 4. Shared power to dispose or direct the disposition: 0
Transactions
Item 5(c) is hereby amended and restated to read as follows: The transactions in the Shares by the Reporting Person since the filing of the original Schedule 13D are set forth in more detail in Exhibit 1 attached hereto.
Other persons with an interest
Item 5(d) is hereby amended and restated to read as follows: No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
Date ownership ceased to exceed 5%
Item 5(e) is hereby amended and restated to read as follows: On 9/30/2026, the Reporting Person ceased to be the beneficial owner of more than five percent of the outstanding Shares. Accordingly, this Amendment No. 1 constitutes an exit filing for the Reporting Person.
Percentage of class
Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares beneficially owned by the Reporting Person is based upon 26,641,597 of the Issuer's shares of Common Stock outstanding as of July 30, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026. As of the close of business on October 2, 2026, the Reporting Person beneficially owned 165,000 Shares. Percentage: Approximately 0.62%
Item 7
Filed exhibits
Exhibit 1: Transactions in the Securities
Signature 1
- Reporting person
- Chernett Jorey
- Signed
- /s/ Jorey Chernett
- Title
- Jorey Chernett
- Date
- 10/02/2026
Filed exhibits
- EX-1 ↗ex1sc13da114528003_10022026.htm
Company context
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 11, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 9, 2026